Zogenix Stock Rating Reaffirmed by Stifel Nicolaus (ZGNX)
Zogenix (NASDAQ:ZGNX)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a research report issued on Friday. They currently have a $3.50 price objective on the stock, down from their previous price objective of $5.00. Stifel Nicolaus’ price target would suggest a potential upside of 123.64% from the stock’s previous close.
Zogenix (NASDAQ:ZGNX) traded down 2.19% during mid-day trading on Friday, hitting $1.565. The stock had a trading volume of 1,137,478 shares. Zogenix has a 1-year low of $1.50 and a 1-year high of $5.19. The stock’s 50-day moving average is $1.83 and its 200-day moving average is $2.98. The company’s market cap is $218.4 million.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.64 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at R. F. Lafferty initiated coverage on shares of Zogenix in a research note on Friday, June 6th. They set a “buy” rating and a $3.50 price target on the stock. They noted that the move was a valuation call. Analysts at William Blair reiterated an “outperform” rating on shares of Zogenix in a research note on Monday, May 12th. They now have a $5.00 price target on the stock, down previously from $6.00.
Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.